Meeting
2011 ASCO Annual Meeting
KRAS and BRAF mutation analysis on paired biopsy and resection specimens of patients with colorectal cancer: Molecular analysis using high-resolution melting, direct sequencing, KRAS ARMS-scorpion PCR and BRAF pyrosequencing.
Authors
L. C. Krol
Isala Clinics, Zwolle, Netherlands
L. C. Krol , N. A. Hart , N. Methorst , A. J. Knol , C. Prinsen , J. E. Boers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Staging
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10609)
Abstract #
10609
Poster Bd #
33B
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota
Poster
2017 Gastrointestinal Cancers Symposium
The treatment continuum of panitumumab, cetuximab, and bevacizumab in 1st through 3rd line by KRAS, NRAS, and BRAF mutation status among mCRC patients treated at community cancer centers in the United States.
First Author: Kimberly Lowe
Poster
2020 ASCO Virtual Scientific Program
Metastases resection in colorectal cancer patients with mutation in oncogene BRAF or tumors located on the right side: Experience at the HGUGM.
First Author: Laura Ortega
Poster
2019 ASCO Annual Meeting
Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs).
First Author: Enrique Aranda